Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Hyperfine, Inc. Class A Common Stock

HYPR

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.

Last trade $0.5764
Day change -$0.0337 (-5.52%)
Day range $0.566 – $0.635
Volume 907,325
Market cap $65M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$64.78M
Price / earnings
—
Price / book
2.04×
Price / sales
3.4×
EV / sales
2.11×
EV / EBITDA
-1.3×

Profitability

Earnings per share
-$0.28
Return on assets
-51.59%
Return on equity
-93.92%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.42×
Current ratio
5.1×
Quick ratio
4.5×
Cash ratio
3.6×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$27.92M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HYPR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$5.96M$3.9M$3.9M$5.29M$3.44M$2.7M$2.14M$2.32M
Cost of revenue$2.58M$1.92M$1.92M$2.6M$1.59M$1.37M$1.25M$1.5M
Gross profit$3.38M$1.98M$1.98M$2.69M$1.85M$1.33M$883K$826K
Selling, general and administrative$6.73M$6.58M$6.69M$6.54M$6.72M$6.38M$6.75M$6.49M
Research and development$3.91M$3.87M$3.85M$3.83M$4.05M$4.54M$5.04M$5.11M
Total operating expenses$10.64M$10.45M$10.54M$10.36M$10.77M$10.92M$11.79M$11.59M
Operating income-$7.26M-$8.47M-$8.56M-$7.67M-$8.92M-$9.6M-$10.9M-$10.77M
Interest expense-$549K-$533K-$83K$0$0$0$0$0
Income before taxes-$5.98M-$9.3M-$8.62M-$5.91M-$11.02M-$9.23M-$9.42M-$10.39M
Income taxes$0$0$0$0$0$0$0$0
Net income-$5.98M-$9.3M-$8.62M-$5.91M-$11.02M-$9.23M-$9.42M-$10.39M
Net income attributable to common shareholders-$5.98M-$9.3M-$8.62M-$5.91M-$11.02M-$9.23M-$9.42M-$10.39M
EBITDA-$7.01M-$8.21M-$8.28M-$7.39M-$8.62M-$9.31M-$10.67M-$10.53M
Basic earnings per share-$0.06-$0.09-$0.09-$0.06-$0.14-$0.12-$0.12-$0.14
Diluted earnings per share-$0.06-$0.09-$0.09-$0.06-$0.14-$0.12-$0.12-$0.14

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

How Decentralized AI is Unlocking Value in Cardiac Diagnostics

Five companies—VentriPoint Diagnostics, HeartBeam, Heartflow, Hyperfine, and GE Healthcare Technologies—are advancing AI-enabled cardiac diagnostic platforms to address the global heart disease crisis. Recent developments include VentriPoint's partnership with First Light Health for remote Indigenous communities, HeartBeam's collaboration with Mount Sinai on AI-ECG algorithms, Heartflow's new clinical registry data, Hyperfine's breakthrough stroke detection results, and GE Healthcare's role in the EU's COMPASS cardiotoxicity initiative.

Benzinga

Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic

AI-driven clinical intelligence is transforming medical imaging, with point-of-care diagnostics projected to reach $70.92 billion by 2032. The CMS ACCESS Model launching in July 2026 will reward outcome-based care, driving adoption of software-defined imaging platforms. Key players including VentriPoint Diagnostics, Butterfly Network, Hyperfine, Hologic, and GE HealthCare are advancing portable, AI-powered diagnostic solutions that deliver hospital-grade precision at the bedside, reducing facility overhead while improving patient outcomes.

The Motley Fool

Hyperfine Q2 Revenue Jumps 26 Percent

Hyperfine reported Q2 2025 results with $2.7 million revenue, 26% sequential increase, and eight system sales. The company achieved FDA clearances, expanded gross margins to 49.3%, and reduced cash burn by 19%, projecting 10-20% revenue growth for the year.

Zacks Investment Research

Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop - Zacks Investment Research

Hyperfine's Swoop system has shown promising results in a study on its ability to quickly assess stroke patients and guide treatment decisions. The study, part of the larger ACTION PMR study, found the Swoop system to be a reliable tool for enabling critical stroke treatment choices in urgent care settings.

Zacks Investment Research

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These are Vita Coco Company (COCO), AMC Entertainment (AMC), Hyperfine (HYPR), Aptevo Therapeutics (APVO) and CLEAR Secure (YOU).

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 13, 20031-for-10reverse split